HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Neutral rating on Inovio Pharmaceuticals (NASDAQ:INO) and maintained a price target of $15.
July 15, 2024 | 10:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated its Neutral rating on Inovio Pharmaceuticals and maintained a price target of $15. This suggests that the analyst does not foresee significant short-term movement in the stock price.
The reiteration of a Neutral rating and maintenance of the price target at $15 indicates that the analyst does not expect significant short-term changes in the stock price. This suggests a stable outlook for the company in the near term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100